New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Abstract

Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers… (More)
DOI: 10.18632/oncotarget.4959

Topics

3 Figures and Tables

Cite this paper

@inproceedings{Bronte2015NewFO, title={New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?}, author={Giuseppe Bronte and Nicola Silvestris and Marta Castiglia and Antonio Galvano and Francesco Passiglia and Giovanni Sortino and Giuseppe Cicero and Christian Rolfo and Marc Peeters and Viviana Bazan and Daniele Fanale and Antonio Giordano and Antonio Russo}, booktitle={Oncotarget}, year={2015} }